Schwab Charles Investment Management Inc. raised its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 9.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 199,659 shares of the company’s stock after buying an additional 17,314 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.51% of Aerie Pharmaceuticals worth $13,487,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Amalgamated Bank raised its stake in Aerie Pharmaceuticals by 20.0% during the 2nd quarter. Amalgamated Bank now owns 5,441 shares of the company’s stock valued at $368,000 after purchasing an additional 906 shares during the period. UBS Group AG grew its holdings in shares of Aerie Pharmaceuticals by 142.3% during the 1st quarter. UBS Group AG now owns 9,409 shares of the company’s stock valued at $511,000 after acquiring an additional 5,526 shares in the last quarter. C WorldWide Group Holding A S grew its holdings in shares of Aerie Pharmaceuticals by 52.4% during the 2nd quarter. C WorldWide Group Holding A S now owns 110,838 shares of the company’s stock valued at $7,487,000 after acquiring an additional 38,099 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of Aerie Pharmaceuticals by 9.2% during the 1st quarter. Prudential Financial Inc. now owns 57,910 shares of the company’s stock valued at $3,142,000 after acquiring an additional 4,890 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Aerie Pharmaceuticals by 8.3% during the 1st quarter. Royal Bank of Canada now owns 32,875 shares of the company’s stock valued at $1,784,000 after acquiring an additional 2,511 shares in the last quarter. 96.00% of the stock is currently owned by institutional investors.

AERI has been the topic of several research analyst reports. ValuEngine cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 26th. BidaskClub cut shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, September 1st. Mizuho restated a “buy” rating and set a $77.00 price target on shares of Aerie Pharmaceuticals in a report on Friday, June 1st. Canaccord Genuity set a $86.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 5th. Finally, Cowen boosted their price target on shares of Aerie Pharmaceuticals from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $83.10.

Shares of NASDAQ:AERI opened at $56.55 on Wednesday. The firm has a market capitalization of $2.67 billion, a P/E ratio of -16.87 and a beta of 0.78. Aerie Pharmaceuticals Inc has a 1 year low of $47.05 and a 1 year high of $74.75. The company has a debt-to-equity ratio of 0.64, a current ratio of 10.27 and a quick ratio of 10.07.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.16). The company had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $1.16 million. equities analysts anticipate that Aerie Pharmaceuticals Inc will post -4.51 EPS for the current year.

In other Aerie Pharmaceuticals news, COO Thomas A. Mitro sold 190,000 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $60.27, for a total transaction of $11,451,300.00. Following the completion of the transaction, the chief operating officer now owns 234,147 shares of the company’s stock, valued at approximately $14,112,039.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Casey C. Kopczynski sold 11,000 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $68.30, for a total transaction of $751,300.00. Following the transaction, the insider now directly owns 163,307 shares of the company’s stock, valued at approximately $11,153,868.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 257,512 shares of company stock valued at $15,670,247. Company insiders own 10.53% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.